Literature DB >> 6505289

Bombesin-like immunoreactivity in human gastrointestinal tract.

J Price, E Penman, J A Wass, L H Rees.   

Abstract

In the present study the distribution and molecular characteristics of bombesin-like immunoreactivity (BLI) were studied in acid extracts of human gastrointestinal tract. The highest levels were found in the fundus, antrum, pylorus and pancreas with lower levels in the duodenum, jejunum, terminal ileum and colon. BLI was also detected in both the muscle and mucosal layers of the antrum and colon. Sephadex G-50 gel chromatography under acid dissociating conditions revealed two peaks of immunoreactivity, one in the position of synthetic porcine gastrin releasing peptide (GRP) and the second eluting with synthetic amphibian bombesin. Variations in the proportions of the two molecular forms were seen in different regions of the gut. In the stomach and pancreas greater than 70% of the BLI eluted with the GRP marker while in pylorus, jejunum and terminal ileum only 20% was present in this form. Reverse-phase ODS silica HPLC of the major antral BLI peak, utilising a methanol/trifluoroacetic acid gradient indicated that this peptide was similar to porcine GRP. We have therefore (1) demonstrated the presence and heterogeneity of bombesin-like immunoreactivity throughout the human gastrointestinal tract and (2) shown for the first time that a proportion of this BLI closely resembles porcine GRP.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6505289     DOI: 10.1016/0167-0115(84)90002-8

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  11 in total

1.  Intramural distribution of regulatory peptides in the sigmoid-recto-anal region of the human gut.

Authors:  G L Ferri; T E Adrian; J M Allen; L Soimero; A Cancellieri; J C Yeats; M Blank; J M Polak; S R Bloom
Journal:  Gut       Date:  1988-06       Impact factor: 23.059

2.  Regulation of gastric function by endogenous gastrin releasing peptide in humans: studies with a specific gastrin releasing peptide receptor antagonist.

Authors:  P Hildebrand; F S Lehmann; S Ketterer; A D Christ; T Stingelin; J Beltinger; A H Gibbons; D H Coy; J Calam; F Larsen; C Beglinger
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

3.  Intramural distribution of immunoreactive vasoactive intestinal polypeptide (VIP), substance P, somatostatin and mammalian bombesin in the oesophago-gastro-pyloric region of the human gut.

Authors:  G L Ferri; T E Adrian; L Soimero; M Blank; D Cavalli; G Biliotti; J M Polak; S R Bloom
Journal:  Cell Tissue Res       Date:  1989-04       Impact factor: 5.249

Review 4.  Endogenous somatostatin and the gut.

Authors:  M R Lucey
Journal:  Gut       Date:  1986-04       Impact factor: 23.059

5.  Characterization of the high-affinity receptors on Swiss 3T3 cells which mediate the binding, internalization and degradation of the mitogenic peptide bombesin.

Authors:  K D Brown; M S Laurie; C J Littlewood; D M Blakeley; A N Corps
Journal:  Biochem J       Date:  1988-05-15       Impact factor: 3.857

6.  Origin of gastrin liberated by gastrin releasing peptide in man.

Authors:  L Lundell; G Lindstedt; L Olbe
Journal:  Gut       Date:  1987-09       Impact factor: 23.059

7.  Bombesin antagonists inhibit in vitro and in vivo growth of human gastric cancer and binding of bombesin to its receptors.

Authors:  Y Qin; G Halmos; R Z Cai; B Szoke; T Ertl; A V Schally
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

8.  The relationship between gastrin cells and bombesin-like immunoreactive nerve fibres in the gastric antral mucosa of guinea-pig, rat, dog and man.

Authors:  A S Miller; J B Furness; M Costa
Journal:  Cell Tissue Res       Date:  1989-07       Impact factor: 5.249

9.  Plasma GRP-like immunoreactivity in healthy and diseased subjects.

Authors:  Y Haraguchi; A Sakamoto; T Yoshida; K Tanaka
Journal:  Gastroenterol Jpn       Date:  1988-06

10.  Bombesin family receptor and ligand gene expression in human colorectal cancer and normal mucosa.

Authors:  H S Chave; A C Gough; K Palmer; S R Preston; J N Primrose
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.